Nectero EAST® System
Stabilization of small to mid-sized Abdominal Aortic Aneurysms (AAA)
Key Facts
About Nectero Therapeutics
Nectero Therapeutics is a private, clinical-stage biotech focused on addressing the significant unmet need in abdominal aortic aneurysm (AAA) management. Its lead program, the Nectero EAST® System, is an investigational endovascular treatment that delivers a proprietary mixture to the aneurysm site, aiming to strengthen the aortic wall and stabilize smaller AAAs, thereby preventing or delaying the need for major surgical interventions like EVAR or open repair. The company's vision is to transform the treatment paradigm for aneurysmal disease by offering an early-intervention option for the large population of patients currently under 'watchful waiting' surveillance. Founded in 2018 and based in Scottsdale, Arizona, Nectero is positioned to potentially revolutionize a standard of care that has seen little innovation for smaller aneurysms.
View full company profile